These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27080693)

  • 1. Rheumatoid arthritis: RA-BEACON illuminates baricitinib.
    Ummarino D
    Nat Rev Rheumatol; 2016 Jun; 12(6):313. PubMed ID: 27080693
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
    Keystone EC; Taylor PC; Drescher E; Schlichting DE; Beattie SD; Berclaz PY; Lee CH; Fidelus-Gort RK; Luchi ME; Rooney TP; Macias WL; Genovese MC
    Ann Rheum Dis; 2015 Feb; 74(2):333-40. PubMed ID: 25431052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib: First Global Approval.
    Markham A
    Drugs; 2017 Apr; 77(6):697-704. PubMed ID: 28290136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib: JAK inhibition for rheumatoid arthritis.
    Gras J
    Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Questioning the Effectiveness of Baricitinib for Pulmonary Manifestations of Rheumatoid Arthritis.
    Chertoff J; Ataya A
    Am J Respir Crit Care Med; 2017 Nov; 196(10):1353. PubMed ID: 28358994
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: Lymphocyte Highs and Lows With Baricitinib.
    Rao DA
    Arthritis Rheumatol; 2018 Dec; 70(12):1897-1900. PubMed ID: 30058141
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA issues concerns about optimal baricitinib doses for the treatment of moderate-to-severe rheumatoid arthritis and delays drug approval.
    Rheumatology (Oxford); 2017 Aug; 56(8):e22. PubMed ID: 28854620
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
    Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
    Iwata S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
    Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
    PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tofacitinib for the treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2016 Jun; 74(6):974-80. PubMed ID: 27311188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
    Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
    EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib for systemic lupus erythematosus.
    Mucke J; Schneider M
    Lancet; 2018 Jul; 392(10143):190-192. PubMed ID: 30043741
    [No Abstract]   [Full Text] [Related]  

  • 17. Baricitinib for systemic lupus erythematosus - Authors' reply.
    Wallace DJ; Furie RA; Tanaka Y; de Bono S; Hoffman RW
    Lancet; 2019 Feb; 393(10170):402-403. PubMed ID: 30712893
    [No Abstract]   [Full Text] [Related]  

  • 18. Baricitinib for systemic lupus erythematosus.
    Yuan K; Huang G; Sang X; Xu A
    Lancet; 2019 Feb; 393(10170):402. PubMed ID: 30712894
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
    Allenbach Y; Bolko L; Toquet S; Landon-Cardinal O; Benveniste O
    Brain; 2019 Mar; 142(3):e9. PubMed ID: 30715158
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.